Measurement of HIV-1 CRF02•AG--Specific T Cell Responses Indicates the Dominance of a p24gag Epitope in Blood Donors in Abidjan, Côte d'Ivoire

Chahroudi, Ann; Sawadogo, Souleymane; Ellenberger, Dennis; Pieniazek, Danuta; Borget-Alloue, Maire-Yolande; Aidoo, Michael; Koblavi-Deme, Stephania; Fernandez-Vina, Marcelo; Maurice, Chantal; Chorba, Terence; Nkengasong, John N.; McNicholl, Janet M.
October 2005
Journal of Infectious Diseases;10/15/2005, Vol. 192 Issue 8, p1417
Academic Journal
Characterization of human immunodeficiency virus (HIV)-1-specific immune responses against subtypes circulating in areas where the virus is endemic is critical for the design of candidate vaccines. In Côte d'Ivoire, the most prevalent HIV-1 subtype is CRF02•AG. We detected T cell responses to CRF02•sensus p24gag protease peptides in 81% of HIV-1- or HIV-1/2-infected blood donors in Abidjan, Côte d'Ivoire. Both the magnitude and the breadth of interferon-γenzyme-linked immuno spot responses were inversely correlated with plasma viral load. One frequently recognized peptide in p24gag as mapped to the optimal epitope (TPQDLNMML). Further studies of this epitope may be important for the development of HIV-1 vaccines for West Africa and West-Central Africa.


Related Articles

  • Fitness Constraints on Immune Escape from HIV: Implications of Envelope as a Target for Both HIV-Specific T Cells and Antibody. Peut, Viv; Kent, Stephen J. // Current HIV Research;Apr2006, Vol. 4 Issue 2, p191 

    Sterilising immunity against HIV-1 infection, whilst ideal, appears an unrealistic vaccination goal in the short term. More achievable is slowing the progression to disease and decreasing transmission by mounting strong T cell and neutralising antibody responses to maintain low viral loads....

  • Where are we going with HIV vaccines? Morris, Lynn; Williamson, Carolyn; Mlisana, Koleka; Gray, Glenda // South African Journal of Science;May/Jun2009, Vol. 105 Issue 5/6, p168 

    The article discusses the HIV vaccines. It states that the undetermined type of immune responses against HIV infection to control viremia is part of the difficulty in making a vaccine against HIV. It adds that the Merck Ad5 vaccine which was designed to stimulate cytotoxic T cells (CTL) showed...

  • Reconsidering Early HIV Treatment and Supervised Treatment Interruptions. Koup, Richard A. // PLoS Medicine;Nov2004, Vol. 1 Issue 2, p109 

    Comments on the use of early HIV treatment and supervised treatment interruptions in the prevention of HIV replication. Effect of antiretroviral treatment on the immune response; Significance of treatment interruptions to T cell immunity; Factors affecting HIV vaccine development.

  • Blunted IL17/IL22 and Pro-Inflammatory Cytokine Responses in the Genital Tract and Blood of HIVExposed, Seronegative Female Sex Workers in Kenya. Chege, Duncan; Chai, Yijie; Huibner, Sanja; Kain, Taylor; Wachihi, Charles; Kimani, Makubo; Barasa, Samson; McKinnon, Lyle R.; Muriuki, Festus K.; Kariri, Anthony; Jaoko, Walter; Anzala, Omu; Kimani, Joshua; Ball, T. Blake; Plummer, Francis A.; Kaul, Rupert; Nixon, Douglas F. // PLoS ONE;Aug2012, Vol. 7 Issue 8, Special section p1 

    Background: Identifying the immune correlates of reduced susceptibility to HIV remains a key goal for the HIV vaccine field, and individuals who are HIV- exposed, seronegative (HESN) may offer important clues. Reduced systemic immune activation has been described in HESN individuals....

  • Transmitted Virus Fitness and Host T Cell Responses Collectively Define Divergent Infection Outcomes in Two HIV-1 Recipients. Yue, Ling; Pfafferott, Katja J.; Baalwa, Joshua; Conrod, Karen; Dong, Catherine C.; Chui, Cecilia; Rong, Rong; Claiborne, Daniel T.; Prince, Jessica L.; Tang, Jianming; Ribeiro, Ruy M.; Cormier, Emmanuel; Hahn, Beatrice H.; Perelson, Alan S.; Shaw, George M.; Karita, Etienne; Gilmour, Jill; Goepfert, Paul; Derdeyn, Cynthia A.; Allen, Susan A. // PLoS Pathogens;Jan2015, Vol. 11 Issue 1, p1 

    Control of virus replication in HIV-1 infection is critical to delaying disease progression. While cellular immune responses are a key determinant of control, relatively little is known about the contribution of the infecting virus to this process. To gain insight into this interplay between...

  • Human ϒδ T lymphocytes in HIV disease: effector functions and control by natural killer cell receptors. Gougeon, Marie-Lise; Poccia, Fabrizio; Boullier, Séverine // Springer Seminars in Immunopathology;2000, Vol. 22 Issue 3, p251 

    Discusses the different activation pathways involved in innate anti-viral function of human gamma/delta T cells and focuses on their role in the context of infection by HIV. Antiviral effector functions of gamma/delta T lymphocytes; Gamma/delta T cell alteration in HIV infection; Speed of...

  • Anti-Human Immunodeficiency Virus Noncytolytic CD8[sup +] T-Cell Response: A Review. Geiben-Lynn, Ralf // AIDS Patient Care & STDs;Oct2002, Vol. 16 Issue 10, p471 

    The CD8[sup +] T-cell immune response for human immunodeficiency virus (HIV) is divided into a cytolytic and noncytolytic mechanism. The mechanism of cell-mediated cytotoxic immunity for the partial control of human immunodeficiency virus type 1 (HIV-1) replication in infected individuals is...

  • Polyvalent AIDS Vaccines. Shan Lu; Serrano, Jill M. Grimes; Wang, Shixia // Current HIV Research;Dec2010, Vol. 8 Issue 8, p622 

    No abstract available.

  • PD-1 Signaling in HIV and Chronic Viral Infection -- Potential for Therapeutic Intervention? Eichbaum, Q. // Current Medicinal Chemistry;Sep2011, Vol. 18 Issue 26, p3971 

    Programmed death-1 (PD-1) is a negative immunoregulatory cell surface receptor molecule whose interaction with its ligands PD-L1 and PD-L2 downmodulates T-cell immune responses. Originally investigated in the context of self-tolerance, PD-1 has more recently been discovered to be upregulated on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics